Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154 on ClinicalTrials.gov · last registry update 2026-09-02
Recruiting now, toward 420 participants. Due to report 1 August 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Sponsor type
- Other
- Enrollment
- 420
- Started
- 2025-09-27
- Primary completion
- 2029-08-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change
Conditions studied
Dementia, Mild · Mild Cognitive Impairment · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.